Article PDF first page preview

First page of Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study

Background: Androgen deprivation therapy (ADT) plus six cycles of docetaxel was the global first-line standard for metastatic hormone-sensitive prostate cancer (mHSPC) before triplet regimens emerged. In many regions, this approach remains the only accessible option. Whether extending docetaxel beyond six cycles provides additional benefit remains uncertain. This study evaluated the efficacy and safety of extended docetaxel in newly diagnosed mHSPC. Methods: We conducted a retrospective cohort study of 98 mHSPC patients treated with ADT plus docetaxel (75 mg/m²) at a German tertiary center (2014–2022). Patients were grouped by treatment duration: 4–6 cycles (n=60) vs. 7–10 cycles (n=38). Progression-free survival (PFS1), time to progression after subsequent therapy (PFS2), and overall survival (OS) were analyzed using Kaplan–Meier and Cox models. Adverse events were graded per CTCAE v5.0. Results: Median PFS1 was similar between groups (12.6 vs. 12.2 months; HR 1.13; p=0.713), as was OS (38.5 vs. 52.9 months; HR 0.99; p=0.958). Extended treatment led to higher overall toxicity (68.4% vs. 38.3%; p=0.004), mainly peripheral neuropathy and dermatologic events, while severe events (grade ≥ 3) were comparable (7.9% vs. 8.3%). Conclusions: Extending docetaxel beyond six cycles in first-line mHSPC offers no survival advantage and increases toxicity. Six cycles remain an effective, pragmatic standard where triplet therapy is unavailable.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2026
You do not currently have access to this content.